PDA relies on document sales to fund the research, task forces, and updates that keep global pharmaceutical standards safe and progressive.

Sterilizing filtration is a critical unit operation in modern biopharmaceutical manufacturing. It ensures the safety and sterility of liquid products that cannot undergo terminal heat sterilization. For decades, the Parenteral Drug Association (PDA) has provided the definitive industry standard for this process through Technical Report No. 26 (TR 26), titled "Sterilizing Filtration of Liquids."

PDA Technical Report 26 remains an indispensable manual for anyone involved in sterile drug manufacturing, quality assurance, or regulatory affairs. By standardizing how liquid filtration is validated, it ensures that sterile products consistently meet the highest safety profiles before reaching patients. When designing a filtration validation strategy, always consult the authorized, current version of TR 26 to ensure full compliance with FDA and EMA expectations.

:

PDA Technical Report No. 26 (TR 26), titled , is a copyrighted publication of the Parenteral Drug Association (PDA) and is not legally available for free download as a complete, current document. However, you can access certain versions or portions through official and professional channels: Official Access & Versions

Evaluation of filter life, compatibility with drug products, and analysis of extractables and leachables.

Utilizing pirated industrial standards violates copyright laws and compromises the professional integrity of a pharmaceutical organization. How to Access PDA TR 26 Legitimately

A: It is strongly recommended that you do not. Regulatory expectations have evolved significantly, especially with the new EU Annex 1. Using the 2008 guidance could lead to non-compliance and a failed regulatory inspection. The 2025 revision is the current industry standard.

Guidance on choosing the most appropriate filter and conducting bacterial retention studies (typically using Brevundimonas diminuta ).

TR 26 emphasizes that validation must be conducted using the actual drug product under worst-case processing conditions (e.g., maximum pressure, temperature, and filtration time), as the formulation can alter bacterial size or filter characteristics. 3. Integrity Testing

Many pharmaceutical companies provide company-wide access to the PDA Bookstore through their internal library systems.

Becoming a PDA member provides more than just a discount. A membership often includes access to a library of technical reports and journal articles as a core benefit. While access may be limited to the "full library" of older reports or require an extra fee for the most current ones, the overall value is immense. As of 2025, PDA membership benefits also included twelve recorded sessions from past annual meetings and access to 24 downloadable resources, showcasing the broad value proposition.

Purchase the document directly from the source.

Total
0
Share